{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679848718976.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2169/internalmedicine.47.1427"}},{"identifier":{"@type":"URI","@value":"http://www.jstage.jst.go.jp/article/internalmedicine/47/21/47_21_1851/_pdf"}},{"identifier":{"@type":"NAID","@value":"130000079581"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2009133313"}}],"dc:title":[{"@language":"en","@value":"Effect of Valsartan Addition to Amlodipine on Insulin Sensitivity in Overweight-Obese Hypertensive Patients"}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"<b>Objective</b> The aim of the study was to evaluate the effect of valsartan/amlodipine combination on insulin sensitivity in overweight-obese hypertensive patients.<br> <b>Methods</b> After a 4-week placebo period, 58 overweight-obese (BMI ≥25 kg/m<sup>2</sup>) patients, with mild to moderate essential hypertension (DBP >95 and <110 mmHg, SBP >140 mmHg) were treated with amlodipine 5 mg od or valsartan 160 mg od or amlodipine 5 mg plus valsartan 160 mg od for 8 weeks according to a randomized, open-label, blinded end-point, cross-over study. At the end of the placebo period and each treatment period, blood pressure (BP) and insulin sensitivity (IS) (by euglycemic hyperinsulinemic clamp technique) were evaluated. IS was expressed as the amount of glucose infused during the last 30 min (glucose infusion rate, GIR) in mg/kg/min.<br> <b>Results</b> Valsartan/amlodipine combination produced a significantly greater decrease in SBP/DBP values (-22.3/16.7 mmHg, p<0.001 vs baseline) than valsartan (-15.2/11.7 mmHg, p<0.01 vs baseline) and amlodipine monotherapy (-16.1/12.6 mmHg, p<0.01 vs baseline). Both valsartan and amlodipine provided a significant increase in GIR (+1.24 mg/kg/min, p=0.036 vs baseline and +1.02 mg/kg/min, p=0.047, respectively), but such an increase was significantly greater with their combination (+1.82 mg/kg/min, p<0.01 vs baseline). These greater changes in IS were not related to BP changes.<br> <b>Conclusion</b> Valsartan/amlodipine combination improved IS more than respective monotherapy beyond affording greater BP reductions. This strengthens the rationale to use valsartan/amlodipine combination in the treatment of overweight-obese hypertensives.<br>"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410282679848718983","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021354774"}],"foaf:name":[{"@language":"en","@value":"Fogari Roberto"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Internal Medicine and Therapeutics, Centro per l'Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679848718981","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021354779"}],"foaf:name":[{"@language":"en","@value":"Preti Paola"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Internal Medicine and Therapeutics, Centro per l'Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679848718980","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021354785"}],"foaf:name":[{"@language":"en","@value":"Zoppi Annalisa"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Internal Medicine and Therapeutics, Centro per l'Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679848718978","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021354791"}],"foaf:name":[{"@language":"en","@value":"Mugellini Amedeo"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Internal Medicine and Therapeutics, Centro per l'Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679848718976","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021354798"}],"foaf:name":[{"@language":"en","@value":"Corradi Luca"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Internal Medicine and Therapeutics, Centro per l'Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679848718982","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021354805"}],"foaf:name":[{"@language":"en","@value":"Lazzari Pierangelo"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Internal Medicine and Therapeutics, Centro per l'Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679848718979","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021354812"}],"foaf:name":[{"@language":"en","@value":"Santoro Tara"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Internal Medicine and Therapeutics, Centro per l'Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679848718977","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021354818"}],"foaf:name":[{"@language":"en","@value":"Derosa Giuseppe"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Internal Medicine and Therapeutics, Centro per l'Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09182918"},{"@type":"EISSN","@value":"13497235"}],"prism:publicationName":[{"@language":"en","@value":"Internal Medicine"},{"@language":"en","@value":"Intern. Med."}],"dc:publisher":[{"@language":"en","@value":"The Japanese Society of Internal Medicine"},{"@language":"ja","@value":"一般社団法人 日本内科学会"}],"prism:publicationDate":"2008","prism:volume":"47","prism:number":"21","prism:startingPage":"1851","prism:endingPage":"1857"},"reviewed":"false","url":[{"@id":"http://www.jstage.jst.go.jp/article/internalmedicine/47/21/47_21_1851/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2009133313"}],"availableAt":"2008","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=valsartan","dc:title":"valsartan"},{"@id":"https://cir.nii.ac.jp/all?q=amlodipine","dc:title":"amlodipine"},{"@id":"https://cir.nii.ac.jp/all?q=insulin-sensitivity","dc:title":"insulin-sensitivity"},{"@id":"https://cir.nii.ac.jp/all?q=overweight","dc:title":"overweight"},{"@id":"https://cir.nii.ac.jp/all?q=obesity","dc:title":"obesity"},{"@id":"https://cir.nii.ac.jp/all?q=hypertension","dc:title":"hypertension"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011144078956544","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145667549952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618481003392","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618548150144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619056069760","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The IGF‐I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619163553408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Obesity-associated activation of angiotensin and endothelin in the cardiovascular system"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619287476864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619651813376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Old antihypertensives and new diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095269545472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570980266240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045003931136","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Olmesartan Ameliorates Insulin Sensitivity by Modulating Tumor Necrosis Factor-.ALPHA. and Cyclic AMP in Skeletal Muscle"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519108314112","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anti-inflammatory and metabolic effects of candesartan in hypertensive patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994277386240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Body Mass Index and the Prevalence of Hypertension and Dyslipidemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994405229568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995895240704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468370634624","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470842943104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944129401600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Obesity as a cardiovascular risk factor"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945214815744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of Calcium Antagonists on Glucose Homeostasis and Serum Lipids in Non-Diabetic and Diabetic Subjects: A Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945619850112","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cardiovascular Pathophysiology of Obesity"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946037421952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946193168128","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hypertension and insulin disorders"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418444113408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418541513344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418661223808","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Differential Control of Systolic and Diastolic Blood Pressure"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419559998080","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of Losartan on Insulin Sensitivity in Hypertensive Subjects"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893837191424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893990532224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895965419136","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368868397952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparison of the Effects of Valsartan and Felodipine on Plasma Leptin and Insulin Sensitivity in Hypertensive Obese Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368957975680","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Leptin and the Cardiovascular System"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368985032320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Comparison of the Effects of Hydrochlorothiazide and Captopril on Glucose and Lipid Metabolism in Patients with Hypertension"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369282456576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369811833216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of hypertension in overweight and obese patients: A practical guide for clinicians"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370853447040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Improved Insulin Action and Glycemic Control After Long Term Angiotensin-Converting Enzyme Inhibition in Subjects with Arterial Hypertension and Type II Diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843397999744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845048928384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Methods for clinical assessment of insulin sensitivity and β-cell function"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318365054464","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Blockade of the renin???angiotensin system decreases adipocyte size with improvement in insulin sensitivity"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319046855424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prospective Randomized Open Blinded End-point (PROBE) Study. A novel design for intervention trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319695951360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320120931584","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Treatment of Arterial Hypertension in Obese Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670321203644160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia."}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793799232384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Obesity and insulin resistance"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795694771584","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Combined Therapy With a Calcium Channel Blocker and an Angiotensin II Type 1 Receptor Blocker"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268562894336","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Combination Therapy With an Angiotensin‐Converting Enzyme Inhibitor and a Calcium Channel Blocker"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269607329152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269810987008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270284253440","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204868208000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effects of the Long-acting Calcium Channel Blockers, Amlodipine, Manidipine and Cilnidipine on Steroid Hormones and Insulin Resistance in Hypertensive Obese Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679695985920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effects of Angiotensin II Receptor Antagonists on Insulin Resistance Syndrome and Leptin in Sucrose-Fed Spontaneously Hypertensive Rats."}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679847969152","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Angiotensin II Type 1 Receptor Blocker Combined with Calcium Channel Blocker for the Treatment of Obese Hypertensive Patients"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0032039720"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.47.1427"},{"@type":"CIA","@value":"130000079581"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.48.1608_references_DOI_ANjQE83XYuUrhVaOkRQmwV1T01b"}]}